Balancing Near-Term Guidance Cuts With Long-Term Growth Drivers: Upholding a Buy on Boston Scientific

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Boston Scientific, with a price target of $100.00.

Matthew Taylor has given his Buy rating due to a combination of factors that balance near-term headwinds with a favorable long-term setup. He acknowledges that Boston Scientific trimmed its 2026 outlook on slower growth in urology, electrophysiology, and WATCHMAN, and that guidance for both revenue and EPS has been reduced, prompting lower estimates and a cut to his price target.

At the same time, he argues the shares remain undervalued given the company’s exposure to faster-growing cardiovascular and structural heart markets and a robust innovation pipeline across multiple high-opportunity therapies. Taylor also expects recent and pending acquisitions, coupled with a sizeable share repurchase program, to support revenue acceleration beyond 2026 and drive further multiple expansion, underpinning his continued Buy recommendation.

In another report released today, Barclays also maintained a Buy rating on the stock with a $100.00 price target.